↑ 薬物リストへ　← 戻る

Famotidine    (DrugBank: Famotidine)

4 diseases
告示番号疾患名（ページ内リンク）臨床試験数
6パーキンソン病1
46悪性関節リウマチ2
86肺動脈性肺高血圧症1
98好酸球性消化管疾患1

6. パーキンソン病　［臨床試験数：2,123，薬物数：2,046（DrugBank：324），標的遺伝子数：183，標的パスウェイ数：198］
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,123 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01937078
(ClinicalTrials.gov)		April 201126/7/2012Famotidine for Levodopa-induced Dyskinesia in PDAn 'N-of-1' Study of the Histamine H@ Antagonist, Famotidine in Levodopa-induced Dyskinesia in Parkinson's DiseaseDyskinesiaDrug: FamotidineUniversity Health Network, TorontoNULLCompleted18 Years80 YearsBoth7Phase 2Canada

46. 悪性関節リウマチ　［臨床試験数：4,183，薬物数：2,538（DrugBank：401），標的遺伝子数：183，標的パスウェイ数：219］
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 4,183 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1JPRN-UMIN000004271
2009/04/0127/09/2010Upper gastrointestinal endoscopic findings in Japanese with rheumatoid arthritis (RA) receiving long-term NSAIDs therapy, and the usefulness of switching to selective COX-2 inhibitor celecoxib Rheumatoid arthritis (RA)NSAIDs-induced gastrointestinal mucosal injuryJapanese rheumatic patients who have been treated with NSAIDs for twelve or more weeks are switched to CEL (400mg/day). Upper GI endoscopy is conducted before and after administration of CEL. Patients with ulcers at the enrollment are switched to CEL (400mg/day) with famotidine (20mg/day) after healing of their pre-existing ulcers following treatment.Hoshigaoka Koseinenkin HospitalNULLComplete: follow-up complete20years-oldNot applicableMale and Female100Not applicableJapan
2NCT00613106
(ClinicalTrials.gov)		September 200728/1/2008Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)Double-Blind Follow-On Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg)in Subjects Who Have Completed Participation in Horizon Protocol HZ-CA-301 (NCT00450658)or Horizon Protocol HZ-CA-303 (NCT00450216)Osteoarthritis;Rheumatoid Arthritis;Chronic Low Back Pain;Chronic Regional Pain Syndrome;Chronic Soft Tissue PainDrug: HZT-501;Drug: IbuprofenHorizon Pharma Ireland, Ltd., Dublin IrelandNULLCompleted40 Years81 YearsAll179Phase 3United States

86. 肺動脈性肺高血圧症　［臨床試験数：1,083，薬物数：667（DrugBank：122），標的遺伝子数：98，標的パスウェイ数：185］
Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 1,083 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03554291
(ClinicalTrials.gov)		May 1, 201931/5/2018Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary HypertensionRepurposing a Histamine Antagonist to Benefit Patients With Pulmonary HypertensionPulmonary Arterial Hypertension;Right Heart FailureDrug: Famotidine 20 MG;Other: PlaceboUniversity of WashingtonNational Heart, Lung, and Blood Institute (NHLBI)Recruiting18 Years80 YearsAll80Phase 2United States

98. 好酸球性消化管疾患　［臨床試験数：128，薬物数：147（DrugBank：40），標的遺伝子数：34，標的パスウェイ数：132］
Searched query = "Eosinophilic gastrointestinal disease", "Eosinophilic gastroenteritis", "Eosinophilic esophagitis", "Eosinophilic colitis", "Eosinophilic gastro-intestinal disorder", "EGID", "Neonatal food-protein induced enterocolitis", "N-FPIES"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 128 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04248712
(ClinicalTrials.gov)		July 10, 202028/1/2020Antihistamines in Eosinophilic EsophagitisA Phase II, Randomized, Placebo-controlled Study Evaluating the Efficacy of Antihistamines in the Treatment of Eosinophilic Esophagitis (the ATEE Study)Eosinophilic EsophagitisDrug: Famotidine;Drug: Loratadine;Drug: PlaceboMayo ClinicNULLRecruiting18 YearsN/AAll50Phase 2United States

先頭へ